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doi:10.1Objective: The 3f Enable aortic bioprosthesis (ATS Medical, Inc, Minneapolis, Minn) represents a new gener-
ation of equine pericardial self-expanding valve designed for sutureless implantation. This study evaluated tech-
nical aspects of implantation and safety and effectiveness of the valve in the short term.
Methods: In an outcome analysis of a consecutive series of 28 patients who underwent aortic valve replacement
for aortic stenosis with the 3f Enable during an 18-month period, mean age was 75.7 6.6 years, 18 patients were
female (64.2%), and mean EuroSCORE was 7.1%  1.7%.
Results: Most implanted valves were 23 mm in diameter (19–27 mm). Mean aortic crossclamp time was 39 15
minutes (29–103 minutes), mean cardiopulmonary bypass time was 58  20 minutes (41–127 minutes), mean
hospital stay was 11 days (7–22 days), and 30-day mortality was 3.5%. Mean and peak intraoperative transvalv-
ular pressure gradients were 6.1 2.6 and 18 5 mm Hg, respectively. Trivial and mild paravalvular leaks were
observed in 1 patient each. One patient underwent reoperative aortic valve replacement 4 months after initial sur-
gery for severe valve-unrelated paravalvular leakage. Five patients (18.5%) required permanent pacemakers. No
patients were unavailable for follow-up. One-year survival was 86.2%.
Conclusions: The 3-f Enable aortic bioprosthesis can be implanted safely with favorable early hemodynamics.
The self-expanding stent allows sutureless implantation with a large valve area. The procedure was fast, although
not as fast as expected. This experience has led to continued design and procedural enhancements to facilitate and
accelerate future implantation. (J Thorac Cardiovasc Surg 2010;140:313-6)Aortic valve replacement (AVR) with cardiopulmonary by-
pass (CPB) is still the treatment of choice for symptomatic
aortic stenosis.1 The procedure can be performed with an ac-
ceptable operative risk, and long-term results are excellent in
terms of quality of life and survival.
The concept of the sutureless valve was initially tested in
the early 1060s,2 with the idea being to facilitate implanta-
tion and shorten ischemic and perfusion times. The concept
was abandoned, however, because of multiple complica-
tions, such as paravalvular leakage and valve-related throm-
boembolic events. Recently, sutureless aortic valve
implantation has received increasing interest because of
the rapid development of transcatheter valve technology.
Shortening the time required for AVR could help to reduce
the morbidity and mortality, especially for patients who re-
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The Journal of Thoracic and Caprocedures. The clinical results reported for the first-genera-
tion 3f Enable sutureless aortic valve prosthesis (ATS Med-
ical, Inc, Minneapolis, Minn) demonstrated feasibility;
however, a high percentage of significant paravalvular leak-
age necessitated device modifications.3 The aim of this study
was to evaluate the second-generation valve regarding its
technical aspects of implantation and its safety and effective-
ness in terms of immediate and short-term clinical and he-
modynamic results.MATERIALS AND METHODS
Patients
The study design was a prospective, nonrandomized, open-label pivotal
trial designed to evaluate the safety and efficacy of the device with a com-
mon clinical investigation plan. Twenty-eight patients who were enrolled at
our institution during an 18-month period underwent AVR with the second-
generation 3f Enable sutureless aortic valve prosthesis (model 6000 3f En-
able; ATS Medical). Patient selection for this type of investigational device
was left to the discretion of the surgeon. Patients received an extensive in-
formational paper describing the new prosthesis, the technology of self-ex-
pansion, and the necessity for close follow-up.
Ten patients were male and 18 were female (64.2%). Mean age was 75.7
 6.6 years (range, 72–89 years). Mean preoperative pressure gradient was
44 17 mm Hg (range, 35–80 mm Hg), and mean aortic valve area was 0.6
 0.2 cm2. Mean EuroSCORE was 7.1%  1.75%. All patients were in
New York Heart Association functional class III or IV.
Postoperative anticoagulation consisted of acetylsalicylic acid (100 mg).
Oral anticoagulation was administered only in the presence of any addi-
tional risk factor (atrial fibrillation, ejection fraction<30%). Follow-uprdiovascular Surgery c Volume 140, Number 2 313
FIGURE 1. Self-expandable 3f Enable aortic valve prosthesis.
FIGURE 2. Valve folded in iced solution.
Abbreviations and Acronyms
AVR ¼ aortic valve replacement
CPB ¼ cardiopulmonary bypass
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Dconsisted of both clinical examinations and intraoperative and postoperative
echocardiography (at discharge and at 6 and 12 postoperative months).
Main exclusion criteria were as follows: patients with previous cardiac sur-
gery, dilated (>4 cm) and severely calcified ascending aorta and aortic root,
and active endocarditis. Combined AVR and myocardial revascularization
was not an exclusion criterion. Discordance between the sinotubular ridge
and diameter of the aortic annulus is not of concern for this type of valve,
because fixation occurs only at the level of the annulus.
The study was approved by the institutional review board of Berne Uni-
versity Hospital. All patients gave written, informed consent.
Description of Implant
The second generation of the 3f Enable sutureless aortic valve prosthesis
(Figure 1) is available from size 19 mm to 29 mm and consists of the follow-
ing: (1) a self-expanding nitinol stent covered with polyester on the inflow
aspect; (2) a 3f aortic bioprosthesis (model 1000; ATS Medical) assembled
from 3 equal sections of equine pericardial material crosslinked with formu-
lations of low-concentration glutaraldehyde under specific parameters of
time, pH, and temperature (this fixation process is aimed at preserving the
collagen architecture of the pericardial material, minimizing the immuno-
genic potential of the xenogeneic tissue, preserving its flexibility and
strength, and optimizing its durability for the intended use); and (3) a poly-
ester flange that conforms to the aortic annulus of the patient (the flange is 2
mm in thickness and should be positioned approximately within the
annulus, covering the removed leaflet remnants). The pliable nitinol stent
allows crimping of the valve at low temperatures (about 5C; Figure 2).
The stent regains its original shape at room temperature because of the mem-
ory effect of the nitinol. The sizer is the true size ATS sizer also available for
the model 1000 3f stentless bioprosthesis.
Implantation Technique
Surgery was performed through a full sternotomy (n ¼ 22) or minister-
notomy (n ¼ 6). Standard CPB was established by cannulation of the as-
cending aorta and the right atrium. Myocardial protection was achieved
with 100 mL antegrade crystalloid single-shot cardioplegia (Cardioplexol;
Bichsel Laboratory, Interlaken, Switzerland). Transverse aortotomy was
performed approximately 2 cm above the commissures. The valve was ex-
cised, and the annulus was decalcified as for conventional AVR.
Sizing of the prosthesis is a crucial step. Neither oversizing nor undersiz-
ing is desirable, because the sizes of the device are really true sizes and it is
not possible to expand an oversized Enable valve in a smaller annulus. After
the usual rinsing, the valve was immersed in ice slurry to allow the folding
and insertion of the stented valve into the applicator (Figure 3). A guiding
stitch was placed at the level of the lowest point of the native annulus in
one of the intracommissural trigones (preferably at the left noncoronary
commissure) to avoid rotation or too-deep insertion of the valve. The stitch
was passed through the suture ring of the valve, and the prosthesis was
pushed out of the applicator. Expansion of the nitinol stented valve was per-
formed with warm saline solution under constant observation. The tabs were
not sutured to the aortic wall but attached to the stent; they came into contact
with the aortic wall after expansion of the valve. Inspection of the coronary
ostia was easy because of the intra-annular position of the valve. The aortot-
omy was closed with a running suture, and the operation was terminated in
the usual way (Figure 4). Position and function of the valve were assessed
by intraoperative transesophageal echocardiography immediately after
weaning from CPB.314 The Journal of Thoracic and Cardiovascular SurgPrimary end points were perioperative mortality and morbidity, includ-
ing all events within 30 days. Follow-up was complete at 6 and 12 months.
Statistical Methods
Common descriptive statistical methods were used. Continuous vari-
ables are summarized as mean  SD when normally distributed and as me-
dian with absolute or interquartile range when asymmetrically distributed.
Categoric variables are presented as numbers with percentages. No compar-
ative statistical analysis was performed.ery c August 2010
FIGURE 5. Explanted valve.
FIGURE 3. Folded valve introduced in release tool.
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DRESULTS
Valve implantation was successful at the first attempt in
25 cases. Twenty-seven patients ultimately received an En-
able valve. In 1 case the valve was too small, probably be-
cause of inappropriate sizing, and it was exchanged for
a stented pericardial tissue valve. In 2 cases the valve was re-
moved immediately after deployment and replaced with an-
other Enable prosthesis a size smaller (21 vs 23 mm).
Prosthesis size ranged from 19 to 27 mm (median size 23
mm). The mean deployment time was 9  11 minutes
(range, 3–25 minutes). Redeployment for less than perfect
alignment with the native valve annulus was necessary in
4 cases. Mean procedural time was 135 70 minutes (range,
85–220 minutes), mean CPB time was 58  20 minutes
(range, 41–127 minutes), and mean crossclamp time was
39.8  5 minutes (range, 29–103 minutes). There were no
intraoperative deaths or complications. Median hospital
stay was 11 days (range, 7–22 days).FIGURE 4. Valve in place, just before closure of aortotomy.
The Journal of Thoracic and CaFollow-up is complete to 18 months. The 30-day in-hos-
pital mortality was 7% (1 patient died of intractable ventric-
ular fibrillation on postoperative day 2 and another died of
intracerebral hemorrhage on day 7). There were 2 additional
deaths during the follow-up period: 1 patient died of gastric
cancer at 3 months and 1 died of terminal heart failure at 7
months. All incidents were considered nonvalve related by
the physician and an independent Data Safety Management
Board (DSMB).
Echocardiographic appearance of the Enable valve was
similar—except for visualization of the stent—to the echo-
cardiographic signature of the normal 3-f stentless valve
and was characterized by an impressively large coaptation
surface. Intraoperative aortic valve area was increased signif-
icantly relative to preoperative values (2.1 0.6 cm2 vs 0.6
0.2 cm2, P< .002), and mean pressure gradient decreased
significantly from a preoperative value of 44  17 mm Hg
to 10.4  4.1 mm Hg at 6 postoperative months (P< .002).
During follow-up, the mean pressure gradient remained
stable relative to the intraoperative value (10  4 mm Hg
at 6 months, 11  2 mm Hg at 12 months). Similarly, the
aortic valve area remained unchanged from the intraopera-
tive finding (2.0  0.4 cm2 at 6 months, 2.1  0.4 cm2 at
12 months). Paravalvular leakage occurred in 3 patients.
Two patients had trivial and mild leakage without hemolysis
and have not required any treatment as of last follow-up. One
patient had significant leakage after 3 months. One month
later, the Enable valve was replaced with a biologic stented
valve. Explantation of the valve was easy, and the valve was
intact (Figure 5). The reason for leakage was not related to
the valve. A localized detachment of the anterior mitral valve
leaflet was found to be related to deep decalcification of the
native aortic annulus.
Permanent pacemaker placement was necessary in 5 cases
(18.5%). Three patients required pacemaker implantation
within the first 12 days, and the other 2 patients received
the pacemaker within 30 days.rdiovascular Surgery c Volume 140, Number 2 315
Acquired Cardiovascular Disease Aymard et alA
C
DDISCUSSION
The 3f Enable sutureless aortic stented valve bioprosthe-
sis represents an innovative approach for surgical AVR.3-5
As transcatheter valve technology has developed rapidly in
the last few years, the devices for surgical AVR have also
improved. The theoretic advantages of the new 3F Enable
prosthesis are the large valve orifice area, comparable to
that of a stentless valve (the nitinol stent is only 1 mm thick),
and the potential for fast implantation and subsequently
shorter CPB time. The latter is advantageous for all patients,
regardless of risk profile. A limited experience with this new
prosthesis has been reported by only 2 groups.4,5
Because of issues with significant paravalvular leakage,
the first-generation device was modified by adding a second
ring of polyester clothing at the inflow part of the valve.3 On
follow-up echocardiography, 2 patients had trivial and mild
paravalvular leakage (1 each), which have remained stable
during an 18-month follow-up and did not necessitate either
surgical intervention or transfusion of red blood cells. Over-
all hemodynamic performance of the valve was satisfying,
with peak gradients similar to those observed with stentless
model of the 3f valve (model 1000)6 The aortic valve area
was similar to that of stentless valves of the same size
(mean 2.1 0.6 cm2, stable at 1 year).7 Because of the small
patient cohort within the study that was predominantly
smaller-sized valves, a superior hemodynamic profile rela-
tive to stentless valves could not be shown.
The reduced time needed for implantation is a theoretic
potential advantage of this new type of valve. In our hands,
the mean crossclamp time was slightly but not significantly
shorter than that needed for stentless valve implantation (39
 15 minutes vs 42 minutes for the Sorin Freedom Solo
stentless valve [Sorin SpA, Milan, Italy]).7 All manipula-
tions with the Enable valve (crimping, insertion into the ap-
plicator, and careful deployment) were part of a learning
process with a short learning curve. The main emphasis in
this pilot trial was therefore not on the time required for im-
plantation. Additional time might be saved by having the as-
sisting surgeon perform the loading of the device; however,
this was not allowed by the protocol of the trial.
No intraoperative complications—such as valve migra-
tion, coronary ostia obstruction, mitral regurgitation, or in-
jury to the ascending aorta—occurred in this series. Three
patients were found to have paravalvular leakage because
of insufficient valve expansion. In 2 cases the valve im-
planted was too large and the nitinol stent could not fully ex-
pand; in these cases, the next smaller valve was implanted
without difficulty. In the other case, the surgeon decided to
proceed with a stented bioprosthesis.
Relative to the series of Martens and colleagues,5 we ob-
served a higher rate of pacemaker implantation (18.5%).316 The Journal of Thoracic and Cardiovascular SurgWe may possibly attribute this phenomenon at our center
to the precondition of the patient and valve placement
within the annulus where there was radial force exerted on
the Hiss bundle at the level of the membranous septum.
The need for permanent pacemaker at our center seems to
be similar to that observed following transcatheter valve
implantation. The rate observed in the more broad patient
cohort within the overall multicenter study appears to be
in the single-digit percentage rate. Generally speaking, the
mortality and morbidity were slightly higher among these
28 patients than among 270 comparable patients (same
mean age, original pathology, average EuroSCORE) who
underwent isolated or combined AVR during the same
period (mortality, 2.2%; pacemaker implantation, 3.1%)
in our institution.8
In conclusion, the second generation of 3f Enable suture-
less valve technology allows favorable clinical and hemody-
namic results. The valve has some similarities to devices
available for transcatheter valve implantation; the main dif-
ference is that the diseased valve can be removed and the an-
nulus decalcified. This allows implantation of a larger valve.
Some time saving may be expected after a short learning
curve of about 10 deployments. This advantage could prove
of major interest for higher risk patients scheduled for more
complex procedures (multivalve or valve and coronary sur-
gery).8 The experience from this study has lead to continued
efforts to enhance the Enable sutureless valve. The next gen-
eration should incorporate more comfortable positioning
and quicker deployment. We hope to be able to show further
reduction of paravalvular leakage and less pacemaker im-
plantation with the new designs.References
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